Quick Links
  : :  Special Issue

Current Issue | July 2009 | Volume 57

Correspondence

ANCA in Graves’ Disease – Is it Anti-Thyroid Medication-Induced?

E Benjamin Samraj Prakash

Associate Professor, School of Medicine, AIMST University, 31 / 2, Bukit Air Nasi, Jalan Bedong Semeling, 08100 Bedong, Kedah Darul Aman, West Malaysia. Received: 21.10.2008; Revised: 6.2.2009; Accepted: 6.3.2009


Sir,

The article by M M Mehndiratta, et al,1 entitled “Carbimazole-induced ANCA positive vasculitis” was informative.1 However, in this case during both episodes steroids have been used. Further, during the first episode the condition improved despite continuing the probable offending drug. Graves’ disease itself is an autoimmune disease and autoantibodies other than thyroperoxidase antibodies are not totally unexpected. Though the study by Sera et al, did not find increased anti-MPO titres in untreated patients, studies that have found increased anti-MPO titres in untreated patients need to be mentioned. Gumà M, et al3 have found that 67% of patients with Graves’ hyperthyroidism show positive ANCA before medical treatment, which points to a relationship with the autoimmune disease itself. The detection of antineutrophil antibodies in Graves’ disease with and without antithyroid medications is known for quite some time.4 Thyroid microsomal antigen (mostly thyroperoxidase) and human myeloperoxidase share 44% amino acid sequence homology and cross-reactivity between thyroid microsomal antigen and human myeloperoxidase has been suggested to be an explanation of this phenomenon.5 However, later studies6,7 have discounted this possibility implying that truly elevated anti-MPO titre is present in untreated patients with Graves’ hyperthyroidism.

References

  1. M M Mehndiratta, S Pandey, RS Kushwaha, et al. Carbimazole induced ANCA positive vasculitis. J Asso Physicians India 2008;56:801-3.
  2. Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves’ disease. Thyroid 2000;10:595-9.
  3. Gumà M, Salinas I, Reverter JL, et al. Frequency of antineutrophil cytoplasmic antibody in Graves’ disease patients treated with methimazole. J Clin Endocrinol Metab. 2003 May;88(5):2141-6.
  4. Sigmund A. Weitzman, Thomas P, et al. Antineutrophil Autoantibodies in Graves‘ Disease. J Clin Invest. 1985;75:119-23.
  5. Haapala AM, Hyoty H, Soppy E, et al. Cross-reactivity between antibodies to thyroid microsomal antigens and myeloperoxidase. Adv Exp Med Biol 1993;336:81–5.
  6. Freire BA, Paula ID, Paula F, et al. Absence of cross-reactivity to myeloperoxidase of anti-thyroid microsomal antibodies in patients with autoimmune thyroid diseases. Am J Med Sci 2001;321:109-12.
  7. Sato H, Hattori M, Fujieda M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves’ disease treated with propylthiouracil. J Clin Endocrinol Metab. 2000;85:4270-3.

Reply from the Author

Sir,

We thank Dr. Benjamin SPE for showing interest in our case report entitled “Carbimazole-Induced ANCA Positive Vasculitis” published in October 2008 issue of JAPI (J Assoc Physicians India 2008;56:801-803).

We have diagnosed our case as drug (carbimazole) induced vasculitis as arthritis and skin rash are not features of Graves’ disease. In Graves’ disease osteopenia and proximal muscle weakness may be seen.1 Our patient developed arthritis and skin rash only after he was given carbimazole. During the first episode the condition improved but patient took the treatment only for 3 weeks and it has been seen that carbimazole-induced vasculitis may be seen after taking the drug for weeks to months. Apart from long-term use, repeated use of antithyroid medication is also a risk factor for developing this disease.2 Steroid was given in our patient as in spite of removing the offending drug patient was very symptomatic. We agree that increased anti-MPO titres may be seen in untreated patients, but in our patient titre normalized after stopping the offending drug.

MM Mehndiratta
Professor of Neurology and Head Unit II, Department of Neurology, GB Pant Hospital, New Delhi 110002
Received: 26.11.2008; Accepted: 6.3.2009

References

  1. Brent GA. Graves’ disease. N Engl J Med 2008:358;2594-604
  2. Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA) – associated autoimmune diseases induced by antithyroid drugs : comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 2005;7:1072-81.
 
Copy rights Association of Physicians of India